Why Context Therapeutics (CNTX) Shares Are Seeing Blue Skies

Context Therapeutics Inc CNTX shares are trading higher by 60.32% to $1.10 Tuesday afternoon after the company announced its clinical trial collaborator, Stemline Therapeutics, received approval from the FDA for ORSERDU in ER+, HER2-, ESR1-mutated breast cancer.

What Else?

Context Therapeutics says ORSERDU has shown improved efficacy over the current standard-of-care (SOC) treatment, fulvestrant, in patients with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer.

See Also: Why AppTech Payments Stock Is Diving 25% Lower

"This is a watershed moment for the industry, which has spent the last 20 years trying to develop a next-generation endocrine therapy that is pharmacologically superior to endocrine monotherapies, including fulvestrant," said Martin Lehr, CEO of Context Therapeutics, said in part of a statement Tuesday.

"ORSERDU has the potential to fundamentally change the treatment paradigm for patients with ESR1-mutated breast cancer, which is found in approximately 40% of the estimated 43,500 patients with metastatic hormone-driven breast cancer in the United States."

According to data from Benzinga Pro, CNTX has a 52-week high of $2.79 and a 52-week low of $0.60.

Market News and Data brought to you by Benzinga APIs
Posted In: NewsPenny Stockswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!